

1. (Twice Amended)

*Sub c1*  
B<sup>1</sup> A method of stimulating or inhibiting nitric oxide synthase in a mammalian subject for the prevention or treatment of certain nitric oxide-mediated pathogenic conditions comprising intravenously administering to the mammal from about 20-500 µg/kg of a peptide, oligopeptide, protein, or L-arginine that acts as a substrate for or an inhibitor of nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase.

3. (Twice Amended)

B<sup>2</sup> The method of claim 1, wherein the peptide, oligopeptide, protein or L-arginine is selected from the group consisting of L-Arginine, Poly-Arginine (M<sub>r</sub> 5,000), SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

10. (Twice Amended)

B<sup>3</sup> A method of preventing or treating a disease or condition in a mammalian subject that is affected by stimulation or inhibition of nitric oxide synthase comprising intravenously administering to the subject in need of such prevention or treatment from about 20-500 µg/kg of a peptide, oligopeptide, protein or L-arginine that acts as a substrate for or an inhibitor of nitric oxide synthase.

13. (Amended)

B<sup>4</sup> The method of claim 10, wherein the peptide, oligopeptide, protein or L-arginine is selected from the group consisting of L-Arginine, Poly-Arginine (M<sub>r</sub> 5,000), SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

---

16. (Amended)

<sup>b<sup>s</sup></sup> A method of stimulating or inhibiting nitric oxide synthase in a mammalian subject for the prevention or treatment of certain nitric oxide-mediated pathogenic conditions comprising intravenously administering to the mammal from about 20-500 µg/kg of a peptide, oligopeptide, protein or L-arginine that acts as a substrate for a nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase, said peptide, oligopeptide or protein being selected from the group consisting of L-Arginine, Poly-Arginine (M<sub>r</sub> 5,000), SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

---

add c<sup>2</sup>